Summary
In late December 2019, COVID-19 was firstly recognized in Wuhan, China and spread rapidly to all of the provinces of China. The West Campus of Wuhan Union Hospital, the designated hospital to admit and treat the severe and critically ill COVID-19 cases, has treated a large number of such patients with great success and obtained lots of valuable experiences based on the Chinese guideline (V7.0). To standardize and share the treatment procedures of severe and critically ill cases, Wuhan Union Hospital has established a working group and formulated an operational recommendation, including the monitoring, early warning indicators, and several treatment principles for severe and critically ill cases. The treatment experiences may provide some constructive suggestions for treating the severe and critically ill COVID-19 cases all over the world.
Article PDF
Similar content being viewed by others
References
Wu Z, Mcgoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 2020
Wang DW, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020,323(11):1061–1069
Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020,579(7798):270–273
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020,395(10223):497–506
Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi (Chinese), 2020,49(0):E009
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet, 2020,395(10223):470–473
National Health Commission. The guidelines for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infection (Pilot 7rd version). [S/OL]. 2020(2020-03-03).
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020,395(10223):507–513
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 2020,382(19):1787–1799
Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Int Med, 2020.
Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect, 2020,81(1):e1–e5
Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect, 2020,81(1):e21–e23
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med, 2020:NEJMoa2007764
Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med, 2020,382(24):2327–2336
Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med, 2017,195(9):1253–1263
Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives [published online ahead of print, 2020 Jun 16]. Nature, 2020:https://doi.org/10.1038/d41586-020-01824-5
Abdolahi N, Kaheh E, Golsha R, et al. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. Trials, 2020,21(1):549
Acknowledgements
We appreciate all of the doctors and nurses who share their valuable experiences and for their hard work in treating COVID-19 patients, and for those who have contributed to translating and proofreading the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that they have no competing interests.
Additional information
The work was supported by COVID-19 Emergency Scientific Research Project of Science and Technology Department, Hubei Province (No. 2020FCA041).
Rights and permissions
About this article
Cite this article
Gao, Y., Qiu, Hb., Zhou, S. et al. Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases. CURR MED SCI 40, 597–601 (2020). https://doi.org/10.1007/s11596-020-2221-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-020-2221-1